AOL

Forget CRISPR Therapeutics: This Gene‑Editing Player Already Boasts the Profits It Dreams Of

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously considered untreatable. That's why biotechs that specialize in gene ...
Investopedia

Vertex Stock Hits Record High on Phase 2 Study Results and Gene-Editing Deal

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
FierceBiotech

After reaching FDA first, CRISPR-Vertex's gene editing therapy will get 'benign' review by committee

A historic moment in pharmaceuticals will happen next week: an FDA advisory committee is set to review the first-ever CRISPR gene editing-based therapy, Vertex Pharmaceuticals and CRISPR Therapeutics’ ...
The Boston Globe

Vertex’s first Crispr gene-editing therapy gets EU backing

Europe’s health regulator followed the United States and the United Kingdom in backing the first gene-editing therapy to use Crispr technology, a Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG ...
Insider Monkey

Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy?

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best ...
Seeking Alpha

CRISPR/Vertex gene editing therapy approved in U.S. for beta-thalassemia

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Tuesday that the U.S. FDA approved its groundbreaking gene editing therapy, Casgevy, developed with CRISPR Therapeutics (NASDAQ:CRSP) for those aged 12 ...
Reuters

Vertex sues US over fertility support program for Casgevy gene editing therapy

July 15 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab sued the U.S. Department of Health and Human Services on Monday, seeking a court declaration that a fertility support program for ...
Hosted on MSN

Forget CRISPR Therapeutics: This gene-editing player already boasts the profits it dreams of

CRISPR Therapeutics' gene-editing platform looks fairly promising, but plenty of challenges could sink the stock. Vertex Pharmaceuticals has a robust underlying business along with some exposure to ...
Bloomberg L.P.

Vertex’s First Crispr Gene Editing Therapy Gets EU Backing

Europe’s health regulator followed the US and UK in backing the first gene-editing therapy to use Crispr technology, a Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG treatment for sickle cell ...